One hundred and forty-six patients (54.7%) received corticosteroids during therapy with anti-PD-(L)1 blockade agents, of whom 134 patients (91.8%) required ≥10 mg of prednisone equivalent per day: 59 patients (44%) for the treatment of irAEs, and 75 patients (56%) for the management of cancer-related symptoms, including asthenia (8.2%) and anorexia (6.3%), symptomatic bone metastases (13.4%), symptomatic brain metastases (36.3%), dyspnea (14.8%), and chronic obstructive pulmonary disease (COPD) management (21%). The gene discussed is CD274; the disease is cancer.